Ortho and BARDA partner on high-specificity antibody tests

17 June 2020 (Last Updated June 17th, 2020 16:26)

Ortho Clinical Diagnostics and the US Biomedical Advanced Research and Development Authority (BARDA) are working together to advance the development of Ortho’s IgG Covid-19 antibody tests.

BARDA has awarded Ortho $678,000 to support the company’s antibody testing programme.

Ortho manufactures two Covid-19 antibody tests: one total antibody test for IgA, IgM and IgG antibodies and one solely for IgG antibodies, which appear in a patient's blood in the later phase of the infection and remain at elevated levels even after recovery. Both have been granted Emergency Use Authorisation (EUA) by the US Food and Drug Administration (FDA).

The tests run on Ortho's high-throughput, fully automated analysers, including its flagship VITROS XT 7600 Integrated System, the VITROS 3600 Immunodiagnostic System, the VITROS 5600 Integrated System and VITROS ECi/ECiQ Immunodiagnostic Systems. They are designed to be administered by professionals and are not for home use.